Zomedica Pharmaceuticals Corp (ZOM) Rise 0.34% on Nov 18

November 18, 2017 - By Vivian Currie

Shares of Zomedica Pharmaceuticals Corp (CVE:ZOM) last traded at 2.99, representing a move of 0.34%, or 0.01 per share, on volume of 245 shares. After opening the trading day at 2.99, shares of Zomedica Pharmaceuticals Corp traded in a close range. Zomedica Pharmaceuticals Corp currently has a total float of 89.34 million shares and on average sees 3,174 shares exchange hands each day. The stock now has a 52-week low of 0.57 and high of 3.

TSX: Leading Canada’s Growth

The equity market is a reliable indicator of any nation’s economic condition. Because of it, investors are able to determine the future of the economy and make investments based on logical numbers.

Canada has one of the world’s fastest growing economies’ thanks to its flourishing equity market that has withstood the toughest of times and still remains thriving until today.

The Canadian Equity Market

The Toronto Stock Exchange (TSX) is the main stock exchange in Canada. The benchmark index weighing its stocks is the S&P/TSX Composite Index, which makes up 70% of the total market capitalization of the TSX.

More than 1,500 companies are listed on the TSX as of October 2014. In May, the total market capitalization of the TSX was seen at nearly $3 trillion.
More than 200 companies are included in the S&P/TSX Composite Index, 36% of which belong to the Financials sector alone. The Energy sector is the second largest sector in the S&P/TSX Composite Index, making up 20% of it, followed by the Materials sector, Industrial sector, and Consumer Discretionary sector in the top five.

The S&P/TSX Composite Index has an all-time low of 217.50 and an all-time high of 15,657.63. Zomedica Pharmaceuticals Corp trades on the exchange.

Trading on the TSX starts and ends at 9:30 a.m. and 4:00 p.m., respectively. Meanwhile, post-market trading starts and ends at 4:15 p.m. and 5:00 p.m., respectively.

How It Works

The S&P/TSX Composite Index measures stocks based on market capitalization with respect to share price. Such is the case to make sure that only the most actively traded stocks represent one of the world’s closely watched indices, providing accurate, real-time manifestations of the Canadian economy. This means that stocks held by the government, company insiders, and venture capitalists are not weighted on the S&P/TSX Composite Index.

For stocks to be included in the S&P/TSX Composite Index, they must first be listed on the TSX under the mandate of the Canadian government. They must make up at least 0.05% of the S&P/TSX Composite Index. This requirement guarantees a harmonious and perfectly balanced index. Zomedica Pharmaceuticals Corp complies with the rules for listing.

Liquidity is also an important consideration in maintaining the S&P/TSX Composite Index. The trading volume of each stock must compose at least 0.025% of the total trading volume of all stocks eligible for inclusion. In terms of price, each stock must have a minimum average trading price of C$1 in the three months immediately preceding the review date. It must also have a minimum trading price of C$1 in the three trading days immediately preceding the rebalancing.

The Organization of the Petroleum Exporting Countries (OPEC) has finally decided to minimize oil production as an answer to the long-time problem of oversupply. This means that crude oil prices are set to bounce back from the turmoil, lifting the TSX further. Consequently, investing on TSX stocks is just reasonable for investors nowadays. Professional analysts might be interested how this will affect Zomedica Pharmaceuticals Corp.

More notable recent Zomedica Pharmaceuticals Corp (CVE:ZOM) news were published by: Nasdaq.com which released: “Zomedica Pharmaceuticals Corp. Expects Trading of its Common Shares on the …” on November 16, 2017, also Globenewswire.com with their article: “Zomedica Pharmaceuticals Corp. Announces NYSE American Listing Approval” published on November 10, 2017, Globenewswire.com published: “Zomedica Pharmaceuticals Corp. to Present at Jefferies 2017 London Healthcare …” on November 08, 2017. More interesting news about Zomedica Pharmaceuticals Corp (CVE:ZOM) were released by: Globenewswire.com and their article: “Zomedica Pharmaceuticals Corp. Announces Third Quarter 2017 Financial Results” published on November 09, 2017 as well as Globenewswire.com‘s news article titled: “Zomedica Pharmaceuticals Corp. Announces US$5M Unsecured Working Capital Loan …” with publication date: October 18, 2017.

Zomedica Pharmaceuticals Corp., formerly Wise Oakwood Ventures Inc., is a veterinary pharmaceutical and healthcare solutions company. The company has market cap of $267.12 million. The Company’s principal business relates to the discovery, development and commercialization of pharmaceuticals for the companion pet. It currently has negative earnings. The Company’s first product candidate, ZM-012, is a tablet formulation of metronidazole, an anti-infective for the treatment of diarrhea in canines .